Cargando…

Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

BACKGROUND: Postoperative readmissions not only burden the healthcare system but may also affect clinical outcomes of cancer patients. Despite this, little is known about readmissions after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), or their impact on survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Eui Whan, Wong, Jolene Si Min, See, Amanda Hui Min, Ong, Whee Sze, Tan, Chee Ann, Ong, Chin-Ann Johnny, Chia, Claramae Shulyn, Soo, Khee Chee, Teo, Melissa Ching Ching, Tan, Grace Hwei Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Peritoneal Surface Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460494/ https://www.ncbi.nlm.nih.gov/pubmed/34304310 http://dx.doi.org/10.1245/s10434-021-10414-2

Ejemplares similares

Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score
por: Rieser, Caroline J., et al.
Publicado: (2021)

Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul, et al.
Publicado: (2021)

Surgeons’ Ability to Predict the Extent of Surgery Prior to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Hentzen, Judith E. K. R., et al.
Publicado: (2020)

Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Leimkühler, Maleen, et al.
Publicado: (2020)

Functional Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Cohort Study
por: Makker, Preet G. S., et al.
Publicado: (2022)

Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021)

Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Thorgersen, Ebbe Billmann, et al.
Publicado: (2021)

Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit
por: Bhutiani, Neal, et al.
Publicado: (2023)

Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Suk Jun, et al.
Publicado: (2021)

RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases
por: Bhullar, Dilraj, et al.
Publicado: (2022)

Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
por: Dietz, Michelle V., et al.
Publicado: (2022)

Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study
por: van Kooten, Job P., et al.
Publicado: (2020)

Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study
por: Kurreck, Annika, et al.
Publicado: (2021)

Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases
por: Ramanathan, Rajesh, et al.
Publicado: (2021)

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of ‘Italian Peritoneal Surface Malignancies Oncoteam—S.I.C.O.’
por: Marano, Luigi, et al.
Publicado: (2021)

In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany
por: Überrück, Lisa, et al.
Publicado: (2020)

A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma
por: Yurttas, Can, et al.
Publicado: (2021)

Biphasic learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:technical competence and refinement of patient selection
por: Shannon, Nicholas B, et al.
Publicado: (2018)

The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Wong, Jolene Si Min, et al.
Publicado: (2020)

Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Wong, Jolene Si Min, et al.
Publicado: (2022)

Use of Prognostic Factors and Scores in Selection of Patients with Colorectal Cancer Peritoneal Metastasis (CRPM) for Cytoreductive Surgery and Intraperitoneal Chemotherapy (CRS/IPC): Results of an International Survey Among Oncologic Clinicians
por: Kozman, Mathew A., et al.
Publicado: (2023)

Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
por: Khan, Sohini, et al.
Publicado: (2022)

The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Tan, Grace Hwei Ching, et al.
Publicado: (2018)

The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer
por: Jónsdóttir, Björg, et al.
Publicado: (2020)

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
por: Di Donato, Violante, et al.
Publicado: (2020)

Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases
por: El Asmar, Antoine, et al.
Publicado: (2022)

Prognostic Impact of Mesenteric Lymph Node Status on Digestive Resection Specimens During Cytoreductive Surgery for Ovarian Peritoneal Metastases
por: Channawi, Ali, et al.
Publicado: (2023)

Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023)

Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases
por: Saito, Shin, et al.
Publicado: (2020)

Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA
por: Raoof, Mustafa, et al.
Publicado: (2023)

Impact of sociodemographic factors on outcomes in patients with peritoneal malignancies following cytoreduction and chemoperfusion
por: Cantos, Adriana, et al.
Publicado: (2022)

Four-Point Computed Tomography Scores for Evaluation of Occult Peritoneal Metastasis in Patients with Gastric Cancer: A Region-to-Region Comparison with Staging Laparoscopy
por: Li, Zi-Yu, et al.
Publicado: (2020)

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019)

Gastric Cancer Peritoneal Carcinomatosis Risk Score
por: Ji, Liang, et al.
Publicado: (2019)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
por: Patrick-Brown, Thale Dawn J. H., et al.
Publicado: (2020)

Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study
por: Bakkers, C., et al.
Publicado: (2021)

HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model
por: Liesenfeld, Lukas F., et al.
Publicado: (2021)

The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis
por: Flood, Michael P., et al.
Publicado: (2022)

In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
por: Said, Ibrahim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fgu3chvm8ask2ssvfelgu870h4